Abstract 463P
Background
Delirium represents global brain dysfunction caused by an underlying medical condition. In cancer, it is associated with worse outcome. Antipsychotic medications have been widely used, however evidence in cancer populations is still limited with concern of potential adverse effects.
Methods
A comprehensive search was conducted among PubMed, EMBASE, Science Direct, and Scopus. Keywords used in this systematic review were antipsychotic agents, delirium, and neoplasm. Publications were limited to English manuscripts published in the last 15 years. Quality of each studies were assessed with Newcastle-Ottawa Scale (NOS).
Results
This review included 11 studies with a total of 1,896 patients aged 23 to 99. The cancer types varied and included lungs, gastrointestinal, hepatobiliary, urological, breast, head and neck, pancreas, lymphoma, sarcoma, and skin cancers. Some studies involved patients with brain metastasis and central nervous system lesions. These studies covered different cancer stages, including advanced, terminal, and localized. The antipsychotic medications examined in this review were haloperidol, quetiapine, chlorpromazine/levomepromazine, olanzapine, risperidone, trazodone, aripiprazole, and perospirone. Both typical and atypical antipsychotics were found to be similarly effective in managing delirium, but typical antipsychotics were associated with a higher prevalence of extrapyramidal symptoms. Higher antipsychotic doses were linked to increased mortality in cancer patients with delirium. Delirium outcomes were assessed using scales such as the Memorial Delirium Assessment Scale (MDAS), Richmond Agitation-Sedation Scale Palliative version (RASS-PAL), and others. Adverse events included hypotension, hypokinesia, sedation, extrapyramidal symptoms, falls, aspiration pneumonia, and urinary retention. Notably, no deaths were reported as a result of antipsychotic therapy.
Conclusions
Antipsychotic interventions to manage delirium in cancer patients consistently showed positive effects in addressing immediate distress and become a meaningful component of end-of-life support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract